Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication

NCT ID: NCT01858870

Last Updated: 2013-05-21

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 860 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-04-30
• Study Completion Date: 2012-12-31

Brief Summary

Lacosamide is an antiepileptic drug approved for using like adjuvant treatment in adults epileptic crisis.

Previous studies has granted to the adjuvant therapy a significant efficacy. This is an observational study, multicenter and retrospective, in patients with epilepsy. The aim of study is the evaluation of the adjuvant treatment with Lacosamide administered over 12 months.

The investigators will collect information from 860 patients in 13 spanish centers.

The secondary aim is assess the tolerability of treatment during 3,6 and 12 month.

Detailed Description

During the treatment we will performed a analysis in three different times (3, 6 and 12 month)for obtain a vision of tolerability and efficacy for Lacosamide in usual clinical practice. We intended describe the differences when we add Lacosamide to an antiepileptic drug, sodium channel blocker or no-sodium channel blocker in usual clinical practice.

Clinical data obtained through post-hoc analysis for registered pivotal studies made in highly refractory epileptic patients show that adjuvant treatment with Lacosamide has an extra efficacy compared with placebo. It is self-depended to the treatment with or without sodium channel blockers.

This study will allow us to obtain information about real existing most population where do not exist as high refractoriness as the pivotal studies.

The population of study is:

Patients with epilepsy, with plus that 18 years old patients, with initial partial crisis treated with Lacosamide according to usual clinical practice in Spain.

Lacosamide must has been used for epilepsy treatment at least during 12 month.

The data record is collection in 5 months.

Inclusion criteria:

1. Adults (+18).

2. Patients with epilepsy partial crisis diagnostic that had been treated with Lacosamide according to usual clinical practice.

3. The patient had at least one partial crisis during the year before to the initiation of treatment with Lacosamide.

4. The patient or their legal agent is reliable and is be able to adhere to the protocol according to the investigation criteria.

Exclusion criteria:

1. Patient is in an other study of medical protocol or medical implant.

2. Patients with other kind of epilepsy.

3. patients with chronic alcoholism or abuse drug recording in the last year.

4. patients who don't be in possession of their faculties in the moment to sign Informed Consent.

Conditions

Epilepsy

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: RETROSPECTIVE

Study Groups

Lacosamide

patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months

lacosamide

Intervention Type: DRUG

routine clinical practice

Interventions

lacosamide

routine clinical practice

Intervention Type: DRUG

Other Intervention Names

Vimpat 50mg; 100mg; 150mg; 200mg

Eligibility Criteria

Inclusion Criteria

1. The patient, male or female, over 18 years.

2. The patient has a diagnosis of prostate cancer of any kind, and has been treated with Lacosamide according to routine clinical practice.

3. The patient had at least one Partial Crisis during the year prior to initiation of treatment with Lacosamide.

4. The patient or their legal representative is reliable and able to adhere to the protocol (ie, is able to understand and complete the interview at the study visit), at the discretion of the investigator.

Exclusion Criteria

1. Patient is participating in another study of a medicinal product research (PMI) or a medical implant.

2. Patients with other types of epilepsy.

3. Patients with a history of chronic alcoholism or drug abuse in the last year.

4. Patients who are not in possession of his faculties at the time of obtaining the Informed Consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Instituto de Investigacion Sanitaria La Fe

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Vicente V Villanueva, doctor

Role: PRINCIPAL_INVESTIGATOR

Iis la Fe

Locations

Iis la Fe

Valencia, Valencia, Spain

Countries

Spain

Other Identifiers

LACO-EXP

Identifier Type: -

Identifier Source: org_study_id